<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02904265</url>
  </required_header>
  <id_info>
    <org_study_id>16-002442</org_study_id>
    <nct_id>NCT02904265</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Acetazolamide Versus Diazepam in Continuous Spike and Wave/Landau-Kleffner Syndrome</brief_title>
  <official_title>Non-inferiority Prospective Randomized Trial of Acetazolamide Versus Diazepam in Patients With Continuous Spike and Wave in Sleep (CSWS)/Landau Kleffner Syndrome (LKS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness of the medications acetazolamide
      and diazepam in the treatment of continuous spike wave in sleep (CSWS) and Landau-Kleffner
      syndrome (LKS).
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spike wave index (SWI) reduction seen in children on acetazolamide</measure>
    <time_frame>within first 4-6 weeks after starting therapy with acetazolamide</time_frame>
    <description>Similar SWI reductions (percentage) comparing acetazolamide and diazepam</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in behaviors (attention, hyperactivity)</measure>
    <time_frame>within 4-8 weeks of initiation of acetazolamide</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in cognitive regression</measure>
    <time_frame>within 4-8 weeks of initiation of acetazolamide</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term tolerability to acetazolamide</measure>
    <time_frame>6 months</time_frame>
    <description>Expect minimal side effects at follow up at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term tolerability of acetazolamide vs diazepam</measure>
    <time_frame>4-8 weeks of start of medications</time_frame>
    <description>Expect improved side effect profile of acetazolamide compared to diazepam at short-term follow up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Landau-Kleffner Syndrome</condition>
  <condition>Status Epilepticus, Electrographic</condition>
  <arm_group>
    <arm_group_label>Diazepam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diazepam 0.5 mg/kg (up to maximum 20 mg) by mouth nightly. Duration of therapy is 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetazolamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acetazolamide 8-10 mg/kg (up to a maximum dose of 375 mg) by mouth (PO)divided twice daily X 1 week, then increased to 11-16 mg/kg (up to a maximum dose of 750 mg) by mouth divided twice daily thereafter. Duration of therapy is 4-8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazepam</intervention_name>
    <arm_group_label>Diazepam</arm_group_label>
    <other_name>Valium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetazolamide</intervention_name>
    <arm_group_label>Acetazolamide</arm_group_label>
    <other_name>Diamox</other_name>
    <other_name>Diamox Sequels</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ESES and clinical CSWS/LKS defined by all of the following:

          -  SWI ≥50% during first hour of sleep

          -  Bilateral synchrony of discharges during sleep

          -  Clinical evidence of behavior and/or academic regression

          -  Daytime SWI ≤20%

        Exclusion Criteria:

          -  Previous treatment with benzodiazepine or acetazolamide for Electrical Status
             Epilepticus in Sleep (ESES)

          -  Current treatment with carbamazepine, phenytoin, oxcarbazepine, phenobarbital,
             vigabatrin or lamotrigine

          -  Antiepileptic medication changes over the month prior to enrollment

          -  Epileptic encephalopathy other than CSWS/LKS

          -  Prior serious adverse reaction to benzodiazepines or acetazolamide

          -  Sulfa allergy

          -  Progressive underlying neurologic condition

          -  Frequent seizures that would prevent the patient from maintaining a stable dose of
             medications

          -  Female patient that has begun menses or is pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine C. Nickels, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fine AL, Wirrell EC, Wong-Kisiel LC, Nickels KC. Acetazolamide for electrical status epilepticus in slow-wave sleep. Epilepsia. 2015 Sep;56(9):e134-8. doi: 10.1111/epi.13101. Epub 2015 Jul 31.</citation>
    <PMID>26230617</PMID>
  </reference>
  <reference>
    <citation>De Negri M, Baglietto MG, Battaglia FM, Gaggero R, Pessagno A, Recanati L. Treatment of electrical status epilepticus by short diazepam (DZP) cycles after DZP rectal bolus test. Brain Dev. 1995 Sep-Oct;17(5):330-3.</citation>
    <PMID>8579219</PMID>
  </reference>
  <reference>
    <citation>Francois D, Roberts J, Hess S, Probst L, Eksioglu Y. Medical management with diazepam for electrical status epilepticus during slow wave sleep in children. Pediatr Neurol. 2014 Mar;50(3):238-42. doi: 10.1016/j.pediatrneurol.2013.11.002. Epub 2013 Nov 12.</citation>
    <PMID>24393416</PMID>
  </reference>
  <reference>
    <citation>Katayama F, Miura H, Takanashi S. Long-term effectiveness and side effects of acetazolamide as an adjunct to other anticonvulsants in the treatment of refractory epilepsies. Brain Dev. 2002 Apr;24(3):150-4.</citation>
    <PMID>11934510</PMID>
  </reference>
  <reference>
    <citation>Sánchez Fernández I, Peters JM, An S, Bergin AM, Takeoka M, Rotenberg A, Kothare SV, Riviello JJ Jr, Loddenkemper T. Long-term response to high-dose diazepam treatment in continuous spikes and waves during sleep. Pediatr Neurol. 2013 Sep;49(3):163-170.e4. doi: 10.1016/j.pediatrneurol.2013.04.027.</citation>
    <PMID>23953953</PMID>
  </reference>
  <reference>
    <citation>Wirrell E, Ho AW, Hamiwka L. Sulthiame therapy for continuous spike and wave in slow-wave sleep. Pediatr Neurol. 2006 Sep;35(3):204-8.</citation>
    <PMID>16939861</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2016</study_first_submitted>
  <study_first_submitted_qc>September 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2016</study_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Katherine C. Nickels</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>continuous spike wave in sleep</keyword>
  <keyword>Landau-Kleffner syndrome</keyword>
  <keyword>acetazolamide</keyword>
  <keyword>diazepam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Status Epilepticus</mesh_term>
    <mesh_term>Landau-Kleffner Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetazolamide</mesh_term>
    <mesh_term>Diazepam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

